Massimo G. Puoti
Expertise in
9
conditions

Massimo G. Puoti

Milan, IT 
Expertise in
9
conditions
Milan, IT 
OverviewLocationsClinical Research

Overview

Massimo Puoti practices in Milan, Italy. Mr. Puoti is highly rated in 9 conditions, according to our data. His top areas of expertise are Hepatitis C, Hepatitis, Cirrhosis, Liver Transplant, and Hepato-Pancreato-Biliary Surgery.

His clinical research consists of co-authoring 241 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Milan, Italy
Other Locations
Monza, 20162, Italy
Grande, Italy
Rome, Italy
Brescia, Italy

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
A Phase 3, Matrix Design, Partially Double-Blind, Randomized Study of the Efficacy and Safety of 50 mg Lonafarnib/100 mg Ritonavir BID With and Without 180 mcg PEG IFN-alfa-2a for 48 Weeks Compared With PEG IFN-alfa-2a Monotherapy and Placebo Treatment in Patients Chronically Infected With Hepatitis Delta Virus Being Maintained on Anti-HBV Nucleos(t)Ide Therapy (D-LIVR)
Enrollment Status: Completed
Publish Date: April 14, 2023
Intervention Type: Drug
Study Drugs: Lonafarnib, Ritonavir, PEG IFN-alfa-2a
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Enrollment Status: Completed
Publish Date: July 28, 2022
Intervention Type: Drug
Study Drug: Baricitinib
Study Phase: Phase 3
View 1 Less Clinical Trial

241 Total Publications

Empirical piperacillin/tazobactam vs carbapenems to treat bloodstream infections due to ESBL enterobacterales: a propensity score-matched observational study conducted in an emergency department in Northern Italy.
Empirical piperacillin/tazobactam vs carbapenems to treat bloodstream infections due to ESBL enterobacterales: a propensity score-matched observational study conducted in an emergency department in Northern Italy.
Journal: Infectious diseases (London, England)
Published: December 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Puoti's expertise for a condition
ConditionClose
    View All 7 Advanced Conditions
    View All 28 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile